M. Michele Blackwood, MD, FACS, Chief, Section of Breast Surgery, Rutgers Cancer Institute of New Jersey, Northern Regional Director of Breast Services, RWJBarnabas Health. In this video, she speaks about the I-SPY2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY).
Description in detail:
I-SPY will compare the efficacy of new medications combined with traditional chemotherapy to the efficacy of standard therapy alone. The goal is to find better treatment regimens for specific subsets based on molecular characteristics (biomarker signatures) of their condition. As with past adaptive trials, regimens that demonstrate a high Bayesian prediction likelihood of being more effective than conventional therapy will be graduated from the study with their accompanying biomarker signature (s). Regimens will be discarded if they have a low likelihood of improved efficacy with any biomarker profile. New medications will enter the market as those that have been tested to complete their review.